Opus Genetics, Inc.
IRD· Nasdaq
IRDOpus Genetics, Inc.
Filed Mar 11, 2021 · 10-K · 70 days after period end · 0001140361-21-008099
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | — | $0.00 | — | — |
| Net Income | -$18.68M | $597.51K | -$3.12M | -$3.59M |
| EPS Diluted | — | — | -$0.09 | -$0.12 |
Opus Genetics, Inc. · CIK 1228627 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2020 · filed Mar 11, 2021 · 70 d after period end
